伏格列波糖/盐酸二甲双胍(Voglibose/Metformin Hydrochloride) - 药物靶点：MGAM x PRKAB1_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Metformin/voglibose、Voglibose/metformin、Vogmet

+ [5]

靶点

MGAM x PRKAB1

作用机制

MGAM抑制剂(麦芽糖酶-糖化酶抑制剂)、PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症-

原研机构

Athena Pharmaceutiques SAS

在研机构

Athena Pharmaceutiques SAS

非在研机构

HK inno.N Corp.

最高研发阶段批准上市

首次获批日期

印度 (2011-01-01),

2型糖尿病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C10H21NO7

InChIKeyFZNCGRZWXLXZSZ-CIQUZCHMSA-N

CAS号83480-29-9

查看全部结构式(2)

关联

6

项与伏格列波糖/盐酸二甲双胍相关的临床试验

NCT05363631 / Recruiting临床1/2期

Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).

开始日期2022-09-19

申办/合作机构

University of Iowa

[+1]

NCT02535533 / Active, not recruiting临床1期

A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma.

开始日期2016-01-01

申办/合作机构

University of Iowa

[+1]

NCT01370707 / Completed临床3期

A Randomized, Double-blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Patients With Type 2 Diabetes and Inadequate Glycemic Control ; Phase III Study

The aim of this study is to evaluate the efficacy and safety fo CJ-30001/CJ-30002.

开始日期2011-04-01

申办/合作机构

HK inno.N Corp.

100 项与伏格列波糖/盐酸二甲双胍相关的临床结果

登录后查看更多信息

100 项与伏格列波糖/盐酸二甲双胍相关的转化医学

登录后查看更多信息

100 项与伏格列波糖/盐酸二甲双胍相关的专利（医药）

登录后查看更多信息

1

项与伏格列波糖/盐酸二甲双胍相关的文献（医药）

2019-01-01·Diabetes & metabolism journal3区 · 医学

Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

3区 · 医学

ArticleOA

作者: Park, Tae Sun ; Cha, Bong Soo ; Jeong, In Kyung ; Son, Hyun Shik ; Park, Joong Yeol ; Choi, Sung Hee ; Kim, In Joo ; Yoon, Kun Ho ; Lee, In Kyu ; Lee, Moon Kyu ; Song, Young Duk ; Baik, Sei Hyun ; Oh, Tae Jung ; Min, Kyung Wan ; Kim, Yong Seong ; Lee, Kwan Woo ; Yu, Jae Myung ; Kim, Sung Rae ; Park, Sung Woo ; Park, Jeong Hyung ; Kim, Doo Man

BACKGROUND:

Combination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naïve newly-diagnosed type 2 diabetes mellitus.

METHODS:

A total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24.

RESULTS:

The reduction in the levels of HbA1c was -1.62%±0.07% in the vogmet group and -1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of <6.5% (P=0.002) or <7% (P=0.039). Glycemic variability was also significantly improved with vogmet treatment, estimated by M-values (P=0.004). Gastrointestinal adverse events and hypoglycemia (%) were numerically lower in the vogmet-treated group. Moreover, a significant weight loss was observed with vogmet treatment compared with metformin (-1.63 kg vs. -0.86 kg, P=0.039).

CONCLUSION:

Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia.

100 项与伏格列波糖/盐酸二甲双胍相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A10BD	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	印度	Athena Pharmaceutiques SAS	2011-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病	临床1期	-	HK inno.N Corp.	2009-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01370707 (Pubmed) 人工标引	临床3期	2型糖尿病	187	Voglibose Plus Metformin	壓壓齋範築遞齋餘簾築(蓋憲壓遞構衊糧憲醖觸) = 壓鬱鏇選衊觸積艱繭衊襯糧憲壓窪築餘憲範鏇 (窪鏇餘範築襯製積築製, 0.07) 更多	优效	2019-06-01
				metformin	壓壓齋範築遞齋餘簾築(蓋憲壓遞構衊糧憲醖觸) = 齋選膚廠網鬱鏇範襯選襯糧憲壓窪築餘憲範鏇 (窪鏇餘範築襯製積築製, 0.07) 更多